Pfizer (PFE) says its Paxlovid forecast assumes that Covid infection rates will again decline in 2026 and “we expect this will be especially true in Q1,” given the current trends. Continues to expect “stable” revenue contributions from non-Covid products portfolio.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PFE:
- Pfizer sees declining Covid trends continuing into next year
- Pfizer in ‘strong position’ to help address substantial unmet needs in obesity
- Pfizer CEO says business ‘not as dependent’ on Covid anymore
- Pfizer Revises 2025 Revenue Guidance to $62 Billion
- Pfizer says ‘on track’ to deliver majority of $7.2B cost savings by 2026